

# Pharmaids Pharmaceuticals Limited

PPL/BSE/4Q/008/2019-20

To,  
The Corporate Relation Department,  
The Stock Exchange, Mumbai,  
1<sup>st</sup> Floor, Rotunda Building,  
Dalal Street, MUMBAI-400001

May 27<sup>th</sup>, 2019

BSE Security Code:524572

**Sub: Outcome of Board Meeting held on May 27<sup>th</sup>, 2019.**

We wish to inform you that the Board Directors of the Company, at their just concluded meeting and Approved the Audited Financial Results of the Company for the Quarter and year ended March 31, 2019 and took note of the Auditors Report thereon


Please find enclosed the audited financial results for Quarter year and year ended March 31, 2019 along with the Auditors Review Report issued by the statutory auditors of the Company.

Further, in compliance with Regulation 33 of Listing Regulations and SEBI Circular No. CFD/DIL3/CIR/2017/21 dated March 10, 2017, the Board hereby declares/certifies that the statutory auditors of the Company have submitted their Audit Report on the standalone financial results of the Company for the FY 2018-19 with an unmodified and unqualified opinion.

The meeting commenced at 11.30 A.M. and concluded at 3.30 P.M.

This for your information and dissemination to the public.

**For PHARMAIDS PHARMACEUTICALS LIMITED**

  
Authorized signatory

CIN No. L52520TG1989PLC009679

Regd. Office : 4-4-211/212/3, Inder Bagh, Sultan Bazar, Hyderabad - 500 095. TELANGANA (INDIA)  
Ph : 040-6666 9809. email : mailpharmaids@yahoo.co.in, Website : www.pharmaids.com

Name of the Company PHARMAIDS PHARMACEUTICALS LIMITED

Statement of Profit and Loss for the Quarter ended 31st March, 2019

Rs. in lakhs

	Particulars	Note No.	Qtr. Ended 31.03.2019	Qtr. Ended audited 31.12.2018	Qtr. Ended audited 31.03.2018	Year Ended Audited 31.03.2019	Year Ended Audited 31.03.2018
I	Revenue From Operations		-	48.10	3.11	48.10	44.91
II	Other Income		0.24	0.03	1.20	0.52	2.01
III	Total Income (I+II)		0.24	48.13	4.31	48.62	46.92
IV	EXPENSES						
	Cost of materials consumed		-	-	0.80	-	3.47
	Purchases of Stock-in-Trade		-	35.62	1.03	35.62	24.19
	Changes in inventories of finished goods, Stock-in-Trade and work-in-progress		-	-	1.05	-	21.78
	Employee benefits expense		0.92	1.13	0.02	2.83	6.30
	Finance costs		0.02	0.12	0.06	0.05	0.14
	Depreciation and amortization expense		0.07	0.02	0.07	0.14	0.11
	Other expenses		4.86	7.75	4.30	24.75	27.79
	Total expenses (IV)		5.87	44.64	7.33	63.39	83.78
V	Profit/(loss) before exceptional items and tax (III-IV)		(5.62)	3.49	(3.02)	(14.77)	(36.86)
VI	Exceptional Items		-	-	-	-	-
VII	Profit/(loss) before tax (V+VI)		(5.62)	3.49	(3.02)	(14.77)	(36.86)
VIII	Tax expense:						
	(1) Current tax Adj. of earlier year		-	-	(0.02)	-	1.73
	(2) Deferred tax		-	-	(0.02)	-	(0.02)
IX	Profit (Loss) for the period from continuing operations (VII-VIII)		(5.62)	3.49	(2.98)	(14.77)	(38.57)
X	Profit/(loss) from discontinued operations		-	-	-	-	-
XI	Tax expense of discontinued operations		-	-	-	(3.70)	-
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)		-	-	-	-	-
XIII	Profit/(loss) for the period (IX+XII)		(5.62)	3.49	(2.98)	(18.47)	(38.57)
XIV	Other Comprehensive Income		-	-	-	-	-
	A (i) Items that will not be reclassified to profit or loss		-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss		-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss		-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss		-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)		-	-	-	-	-
XVI	Earnings per equity share (for continuing operation):						
	(1) Basic		(0.17)	0.10	(0.09)	(0.54)	(1.13)
	(2) Diluted		(0.17)	0.10	(0.09)	(0.54)	(1.13)



XVII	Earnings per equity share (for discontinued operation):		-	-	-	-	-
	(1) Basic		-	-	-	-	-
	(2) Diluted		-	-	-	-	-
XVII	Earnings per equity share (for discontinued & continuing operations)		-	-	-	-	-
1	(1) Basic		-	-	-	-	-
	(2) Diluted		-	-	-	-	-

**Notes:**

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 27th May, 2019. 2. The Audited Financial Results for the Quarter 4 and ended 31st March, 2019 have been prepared and reviewed by the Statutory Auditors in pursuance of Schedule III of Companies Act, 2013. 3. The figures of the previous year/periods have been re-grouped/re-classified, whenever necessary, for the purpose of comparison. a. 4) The company operates in a single segment and the results pertain to a single segment i.e., drug formulation only. 5) The Hon'ble NCLT, Hyderabad conveyed Share holders General Meeting held on 11-05-2019, where in the Share holders has approved the Scheme of Amlagamation with Emergent Bio Naturals Ltd

**Place : Hyderabad**

**Date : 27-05-2019**

For : *[Signature]* **Managing Director**

*[Signature]*

**Managing Director**

Chartered Accountants  
**PPKG & Co**

Independent Auditor's Report on Quarterly Financial Results and Year to Date Results of PHARMAIDS PHARMACEUTICALS LTD pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

TO THE BOARD OF DIRECTORS OF PHARMAIDS PHARMACEUTICALS LTD

1. We have audited the annual financial results of PHARMAIDS PHARMACEUTICALS LTD (the "Company") for the year ended 31st March, 2019 ("annual financial results"), attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Listing Regulations'). Attention is drawn to the fact that the figures for the last quarter ended 31st March 2019 and the corresponding quarter ended in the previous year as reported in the annual financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of the third quarter of the relevant financial year. Also the figures up to the end of the third quarter had only been reviewed and not subjected to audit. These annual financial results have been prepared on the basis of the annual financial statements and reviewed quarterly financial results which are the responsibility of the Company's Management. Our responsibility is to express an opinion on these annual financial results based on our audit of the annual financial statements which have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 as per Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the annual financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by the management, we believe that our audit provides a reasonable basis for our opinion.
3. In our opinion and to the best of our information and according to the explanations given to us, these financial results, except the sundry Debtors/Sundry Creditors/Receivables/Payables are subject to confirmation and reconciliation.
  - a) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
  - b) give a true and fair view of the net profit, other comprehensive income and other financial information for the year ended 31st March, 2019.



- 4 We draw attention to Note 5 of the accompanying result regarding Scheme of Amalgamation. The Hon'ble NCLT, Hyderabad conveyed Share holders General Meeting held on 11-05-2019, where in the Shareholders has approved the Scheme of Amalgamation with Emergent Bio Naturals Ltd. Pending final approvals from Hone'ble NCLT, no effect of the above mentioned scheme has been given in financial statements for the year ended 31<sup>st</sup> March, 2019.

Our Opinion is not modified in respect of this matter.

for PPKG & Co  
Chartered Accountants  
Firm Reg No: 0096555

  
Giridhari Toshniwal  
Partner  
Membership No.205140





# Pharmaids Pharmaceuticals Limited

Statement of Assets & Liabilities as on 31st March 2019

(Amount In Rupees)

ASSETS	As at 31 March 2019	As at 31 March 2018
<b>1 Non-current assets</b>		
Property, plant and equipment	24,884	22,512
Financial assets		
- Non-Current Assets	-	5,30,000
- Long-term loans and advances	43,35,842	48,80,256
- Others		
Deferred tax assets (Net)	(3,67,928)	1,816
Other non-current assets	-	-
<b>2 Current assets</b>		
Inventories	-	-
Financial assets		
- Trade and other receivables	53,62,208	51,55,587
- Cash and cash equivalents	10,67,500	23,63,716
- Short term loans and advances	-	-
Other current assets	-	-
<b>TOTAL ASSETS</b>	<b>1,04,22,506</b>	<b>1,29,53,887</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Share capital	3,36,30,850	3,36,30,850
Other equity		
- Equity component of other financial instrument		
- Retained earnings	(2,50,57,639)	(2,32,10,753)
<b>Share application money pending allotment</b>		
<b>1 Non-current liabilities</b>		
Financial liabilities		
- Long term borrowings	-	-
Long term provisions	-	-
Deferred tax liabilities (Net)	-	-
Other non-current liabilities	-	2,52,375
<b>2 Current liabilities</b>		
Financial liabilities		
- Short term borrowings	-	-
- Trade and other payables	15,96,033	18,47,985
Other current liabilities	2,53,262	4,33,430
Short-term provisions	-	-
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>1,04,22,506</b>	<b>1,29,53,887</b>

See accompanying notes to the financial statements 27

As per our report of even date attached

For PPKG & CO

Chartered Accountants  
Firm Registration Number: 009655S

Girdhari Toshniwal  
Partner  
Membership Number: 205140

Place: Hyderabad  
Date: 27/05/2018

For. Pharmaids Pharmaceuticals Limited

Dr. Ghisulal Jain [DIN No.00404983]

Chairman & Managing Director

Seema Jain

Director & CEO [DIN No.718351]

CIN No. L52520TG1989PLC009679

Regd. Office : 4-4-211/212/3, Inder Bagh, Sultan Bazar, Hyderabad - 500 095. TELANGANA (INDIA)

Ph : 6559 9809, Tele Fax : 040-2756 2126. email : mailpharmaids@yahoo.co.in, Website : www.pharmaids.com

Unit : Survey No. 533, (V) Kondamadugu, (M) Bibi Nagar, District Nalgonda (Telangana). Phone : +91-92470 58492